Literature DB >> 7932286

Patterns of substance abuse in schizophrenia: nature and significance.

J R DeQuardo1, C F Carpenter, R Tandon.   

Abstract

Recent literature suggests that the increasingly prevalent problem of substance abuse may have important implications for the symptoms and course of schizophrenia. To further examine the impact of substance abuse on this disorder, the clinical and research charts of 67 schizophrenic patients admitted to the Schizophrenia Program of the University of Michigan between 1987 and 1990 were reviewed and data on symptomatology, history of substance use, age at onset and first hospitalization, and family psychiatric history were gleaned. This information was analyzed with respect to clinical, demographic, and outcome variables with the following findings: (i) female subjects abused substances at a much lower rate (20%) than male subjects (48%); (ii) substance-abusing patients with schizophrenia had lower pre- and post-treatment Hamilton Rating Scale of Depression scores, poorer post-discharge treatment compliance, and were younger at first hospitalization than were non-abusing patients; (iii) the most often abused substance was cannabis (28%) followed closely by alcohol (21%), with cocaine, hallucinogens, and stimulants all abused by significantly fewer patients; (iv) rates of family history of schizophrenia were similar in substance-abusing and non-substance-abusing schizophrenic patients. These data suggest that substance abuse may not be etiologically related to schizophrenia but influences the onset, course, and symptomatology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7932286     DOI: 10.1016/0022-3956(94)90010-8

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  19 in total

Review 1.  Improving the quality of the cannabis debate: defining the different domains.

Authors:  J Strang; J Witton; W Hall
Journal:  BMJ       Date:  2000-01-08

2.  Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia.

Authors:  R Andrew Chambers; David W Self
Journal:  Neuropsychopharmacology       Date:  2002-12       Impact factor: 7.853

3.  Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis.

Authors:  Michael T Compton; Beth Broussard; Claire E Ramsay; Tarianna Stewart
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

Review 4.  Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Authors:  David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Meta-analysis of self-reported substance use compared with laboratory substance assay in general adult mental health settings.

Authors:  Matthew M Large; Glen Smith; Grant Sara; Michael B Paton; Karina Karolina Kedzior; Olav B Nielssen
Journal:  Int J Methods Psychiatr Res       Date:  2012-02-27       Impact factor: 4.035

Review 6.  Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.

Authors:  Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss
Journal:  J Psychiatr Pract       Date:  2005-09       Impact factor: 1.325

Review 7.  The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.

Authors:  John H Krystal; D Cyril D'Souza; Jürgen Gallinat; Naomi Driesen; Anissa Abi-Dargham; Ismene Petrakis; Andreas Heinz; Godfrey Pearlson
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

8.  Reported comorbidity of mental disorders with substance abuse among psychiatric inpatients in Israel.

Authors:  J Rabinowitz; M Mark; M Popper; M Slyuzberg
Journal:  J Ment Health Adm       Date:  1996

Review 9.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

10.  A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.

Authors:  Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green
Journal:  J Dual Diagn       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.